Curcumin inhibits tyrosine kinase activity of p185(neu) and also depletes p185(neu1)

Clinical Cancer Research

Volumn 5, Issue 7, 1999, Pages 1884-1891

  Hong, Ruey Long ^a,b   Spohn, William H ^b   Hung, Mien Chie ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; CURCUMIN; GLUCOSE REGULATED PROTEIN; ONCOPROTEIN; PROTEIN P185; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; CURCUMA LONGA; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; ONCOGENE C ERB; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL DIVISION; COLONY-FORMING UNITS ASSAY; CURCUMIN; ENZYME INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; KINETICS; MEMBRANE PROTEINS; MOLECULAR WEIGHT; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; SUBCELLULAR FRACTIONS; TUMOR CELLS, CULTURED;

EID: 0032789660     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Huang, M. T., Wang, Z. Y., Georgiadis, C. A., Laskin, J. D., and Conney, A. H. Inhibitory effects of curcumin on tumor initiation by benzo[a]pyrene and 7.12-dimethylbenz[a]anthracene. Carcinogenesis (Lond.), 13: 2183-2186, 1992.
2. Huang, M. T., Ma, W., Lu, Y. P., Chang, R. L., Fisher, C., Manchand, P. S., Newmark, H. L., and Conney, A. H. Effects of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion. Carcinogenesis (Lond.), 16: 2493-2497, 1995.
3. Liu, J. Y., Lin. S. J., and Lin, J. K. Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells. Carcinogenesis (Lond.), 14: 857-861, 1993.
4. Korutla, L., and Kumar, R. Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells. Biochim. Biophys. Acta, 1224: 597-600, 1994.
5. Korutla, L., Cheung, J. Y., Mendelsohn, J., and Kumar, R. Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. Carcinogenesis (Lond.), 16: 1741-1745, 1995.
6. Yamamoto, T., Ikawa, S., Akiyama, T., Semba, K., Nomura, N., Miyajima, N., Saito, T, and Toyoshima, K. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature (Lond.), 319: 230-234, 1986.
7. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Washington DC), 235: 177-182, 1987.
8. Chazin, V. R., Kaleko, M., Miller, A. D., and Slamon, D. J. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene, 7: 1859-1866, 1992.
9. Yu, D. H., and Hung, M. C. Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene, 6: 1991-1996, 1991.
10. Yu, D., Wolf, J. K., Scanlon, M., Price, J. E., and Hung, M-C. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res., 53: 891-898, 1993.
11. Yu, D., Wang, S-S., Dulski, K. M., Tsai, C-M., Nicolson, G. L., and Hung, M-C. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res., 54: 3260-3266, 1994.
12. Xing, X., Matin, A., Yu, D., Xia, W., Sorgi, F., Huang, L., and Hung, M. C. Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu overexpressing ovarian cancer. Cancer Gene Ther., 3: 168-174, 1996.
13. Yu, D., Matin, A., Xia, W., Sorgi, F., Huang, L., and Hung, M. C. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene, 11: 1383-1388, 1995.
14. Zhang, Y., Yu, D., Xia, W., and Hung, M. C. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene, 10: 1947-1954, 1995.
15. Drebin, J. A., Link, V. C., Weinberg, R. A., and Greene, M. I. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc. Natl. Acad. Sci. USA, 83: 9129-9133, 1986.
16. Drebin, J. A., Link, V. C., and Greene, M. I. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effect in vivo. Oncogene, 2: 273-277, 1988.
17. neu receptor. Nat. Med., 1: 644-648, 1995.
18. Park, J. W., Hong, K., Carter, P., Asgari, H., Guo, L. Y., Keller, G. A., Wirth, C., Shalaby, R., Kotts, C., Wood, W. I., Papahadjopoulos, D., and Benz, C. C. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA, 92: 1327-1331, 1995.
19. Zhang, L., Chang, C-j., Bacus, S. S., and Hung, M-C. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. Cancer Res., 55: 3890-3896, 1995.
20. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, I. C., and Norton, L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol., 14: 737-744, 1996.
21. Rao, C. V., Rivenson, A., Simi, B., and Reddy, B. S. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res., 55: 259-266, 1995.
22. Soni, K. B., and Kuttan, R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J. Physiol. Pharmacol., 36: 273-275, 1992.
23. Mazzarella, R. A., and Green, M. ERp99, an abundant, conserved glycoprotein of the endoplasmic reticulum, is homologous to the 90-kDa heat shock protein (hsp90) and the 94-kDa glucose regulated protein (GRP94). J. Biol. Chem., 262: 8875-8883, 1987.
24. neu: a relationship between disruption of this regulation and transformation. Proc. Natl. Acad. Sci. USA, 92: 1092-1096, 1995.
25. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
26. Rubinstein, L. V., Shoemaker, R. H., Paull, K. D., Simon, R. M., Tosini, S., Skehan, P., Scudiero, D. A., Monks, A., and Boyd, M. R. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst., 82: 1113-1118, 1990.
27. erbB2. J. Biol. Chem. 271: 4974-4977, 1996.
28. Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M., and Fukami, Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem., 262: 5592-5595, 1987.
29. c-erb-2 receptor protein-kinase induced by geldanamysin. J. Biol. Chem, 271: 22796-22801, 1996.
30. Levitzki, A. Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J., 3275-3282, 1992.
31. Miller, P., Schnur, R. C., Barbacci, E., Moyer, M. P., and Moyer, J. D. Binding of benzoquinoid ansamycins to p100 correlates with their ability to deplete the erbB2 gene product p185. Biochem. Biophys. Res. Commun., 207: 1313-1319, 1994.
32. Levitzki, A., and Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science (Washington DC), 267: 1782-1788, 1995.
33. Li, Z., and Srivastava, P. K. Tumor rejection antigen gp96/grp94 is an ATPase: implications for protein folding and antigen presentation. EMBO J., 12: 3143-3151, 1993.
34. Singh, S., and Aggarwal, B. B. Activation of transcription factor NF-κB is suppressed by curcumin (diferuloymethane). J. Biol. Chem., 270: 24995-25000, 1995.
35. Chen, Y. R., and Tan, T. H., Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene, 17: 173-178, 1998.
36. Chen, H. W., and Huang, H. C., Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells. Br. J. Pharmacol., 124: 1029-1040, 1998.
37. Jee, S. H., Shen, S. C., Tseng, C. R., Chiu, H. C., and Kuo, M. L. Curcumin induces a p53-dependent apoptosis in human basal cell carcinoma cells. J. Invest. Dermatol., 111: 656-661, 1998.
38. Jaruga, E., Salvioli, S., Dobrucki, J., Chrul, S., Bandorowicz-Pikula, K., Siskora, E., Franceschi, C., Cossarizza, A., and Bartosz, G., Apoptosis-like, reversible changes in plasma membrane asymmetry and permeability, and transient modifications in mitochondrial membrane potential induced by curcumin in rat thymocytes. FEBS Lett., 433: 287-293, 1998.